CM
IONS icon

Crestline Management’s Ionis Pharmaceuticals IONS Stock Holding History

Crestline Management’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-21,450
Closed -$894K – 190
2018
Q2 		$894K Sell
21,450
-4,103
-16% -$182K 0.09% 203
2018
Q1 		$1.13M Buy
25,553
+27
+0.1% +$1.37K 0.14% 135
2017
Q4 		$1.28M Sell
25,526
-25,431
-50% -$1.39M 0.13% 88
2017
Q3 		$2.58M Buy
+50,957
New +$2.67M 0.36% 45

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Crestline Management's IONS Position: Q3 2018 in Review

Crestline Management sold out of Ionis Pharmaceuticals (IONS) in Q3 2018, closing a stake of 21,450 shares — an estimated $894K sold.

Crestline Management first reported a position in IONS in Q3 2017 and held it in 4 quarters. The position peaked at $2.58M in Q3 2017. 322 funds tracked by Wall St. Rank hold IONS as of Q3 2018.

  • Crestline Management reported no remaining Ionis Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
  • Crestline Management sold 21,450 Ionis Pharmaceuticals shares in Q3 2018, an estimated $894K.
  • Crestline Management first reported a position in Ionis Pharmaceuticals in Q3 2017 and held it in 4 quarters.
  • Crestline Management's Ionis Pharmaceuticals position peaked at $2.58M in Q3 2017.
  • 322 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q3 2018.

Based on Crestline Management's 13F filing for Q3 2018, filed 14 Nov 2018.